PRIME Study Findings on Gemini: New Horizons in CKD and AKI Management

Revelation Biosciences Inc. is set to unveil promising new clinical data on its investigational therapy, Gemini, during the upcoming International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026), taking place March 29 through April 1 in San Diego.

The presentation will spotlight findings from the recently completed PRIME clinical study, reinforcing Gemini’s potential in treating both acute kidney injury (AKI) and chronic kidney disease (CKD).

Robin Marsden, Senior Vice President of Biology at Revelation, will present the data during a dedicated session on March 29. Titled “Gemini restores normal innate immune response in CKD patients,” the presentation will focus on Gemini’s ability to normalize the hyperinflammatory state observed in stage 3 and 4 CKD patients and to restore immunocompetence—an essential step in curbing disease progression.

Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. By targeting TLR4, the compound rebalances the innate immune system and is being developed for diseases characterized by dysregulated inflammation. In addition to its application in AKI and CKD, Gemini is being investigated as a potential treatment to reduce infection risk in patients with severe burns (GEM-PBI) and to prevent post-surgical infection (GEMINI-PSI).

AKI remains a significant global health challenge, affecting over 10% of hospitalized patients and more than half of those admitted to intensive care units. Severe AKI often requires dialysis—currently the only therapeutic option for managing its consequences—and carries a high risk of mortality. Even among survivors, nearly 40% will go on to develop chronic kidney disease or end-stage renal disease.

Given the critical need for new therapeutic options, Gemini’s ability to restore immune balance in CKD patients and prevent inflammation-driven organ damage positions it as a potentially transformative treatment. The new data from Revelation’s PRIME study offer additional support for this approach, following successful demonstration of Gemini’s activity in preclinical models and two prior phase 1 trials.

Revelation Biosciences is a clinical-stage life sciences company dedicated to addressing inflammatory disease through immune system modulation. The company’s pipeline programs reflect a focused strategy to tackle both acute and chronic conditions with high unmet medical need, using its proprietary Gemini platform.

The company’s presentation at AKI & CRRT 2026 underscores its growing presence in the nephrology space and its commitment to advancing meaningful innovation in inflammation-driven kidney disease.

Key Takeaways:

• Interim PRIME data show Gemini reduces biomarkers of hyperinflammation in patients with advanced CKD.
• Early signals suggest improved immunocompetence, which may reduce infection risk if confirmed in larger studies.
• Findings are interim; confirmatory randomized trials and full safety reporting are needed before practice change.